Conversely, it has been suggested that patients with NSCLC who received PD-1 inhibitors tended to exhibit a higher incidence of organ-specific irAE compared to patients treated with PD-L1 inhibitors, particularly in the digestive system (Sun et al., 2019). This evidence concerns the gene CD274 and non-small cell lung carcinoma.